Jonathan Yen-Wen Yu Sells 1,610 Shares of Disc Medicine, Inc. (NASDAQ:IRON) Stock

Disc Medicine, Inc. (NASDAQ:IRON) COO Jonathan Yen-Wen Yu sold 1,610 shares of the business’s stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $54.58, for a total transaction of $87,873.80. Following the completion of the sale, the chief operating officer now directly owns 40,555 shares in the company, valued at approximately $2,213,491.90. This represents a 3.82 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Disc Medicine Stock Up 0.3 %

Shares of NASDAQ IRON opened at $54.52 on Friday. The firm has a market cap of $1.62 billion, a PE ratio of -13.70 and a beta of 0.73. The company’s fifty day simple moving average is $59.05 and its 200 day simple moving average is $55.10. Disc Medicine, Inc. has a 12-month low of $25.60 and a 12-month high of $77.60.

Hedge Funds Weigh In On Disc Medicine

Institutional investors and hedge funds have recently made changes to their positions in the stock. FMR LLC increased its position in Disc Medicine by 358.7% in the 4th quarter. FMR LLC now owns 1,866,248 shares of the company’s stock valued at $118,320,000 after buying an additional 1,459,434 shares in the last quarter. Janus Henderson Group PLC grew its stake in Disc Medicine by 62.4% in the fourth quarter. Janus Henderson Group PLC now owns 1,217,815 shares of the company’s stock valued at $77,170,000 after acquiring an additional 467,988 shares during the period. Price T Rowe Associates Inc. MD increased its holdings in shares of Disc Medicine by 23.2% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 1,394,637 shares of the company’s stock valued at $88,421,000 after acquiring an additional 262,690 shares in the last quarter. State Street Corp raised its position in shares of Disc Medicine by 39.7% during the third quarter. State Street Corp now owns 827,910 shares of the company’s stock worth $40,683,000 after purchasing an additional 235,115 shares during the period. Finally, Raymond James Financial Inc. bought a new position in shares of Disc Medicine in the 4th quarter worth $5,579,000. Institutional investors own 83.70% of the company’s stock.

Analyst Ratings Changes

Several brokerages have commented on IRON. HC Wainwright reaffirmed a “buy” rating and set a $118.00 target price on shares of Disc Medicine in a report on Tuesday, January 21st. Stifel Nicolaus lifted their price objective on Disc Medicine from $90.00 to $94.00 and gave the stock a “buy” rating in a research note on Friday, January 24th. Morgan Stanley raised shares of Disc Medicine from an “equal weight” rating to an “overweight” rating and set a $85.00 target price for the company in a research report on Tuesday, November 5th. Raymond James upgraded shares of Disc Medicine from an “outperform” rating to a “strong-buy” rating and raised their price target for the stock from $66.00 to $110.00 in a report on Monday, November 4th. Finally, Scotiabank upped their price objective on shares of Disc Medicine from $70.00 to $73.00 and gave the company a “sector outperform” rating in a research note on Wednesday, January 22nd. Nine investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, Disc Medicine has a consensus rating of “Buy” and a consensus price target of $88.90.

Disc Medicine Company Profile

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.